WHERE THE EVIDENCE STANDS
The animal literature is large and comes mostly from one group at the University of Zagreb. It reports faster healing of tendon, muscle and gut tissue and effects on blood-vessel formation. As of October 2026 no randomised, placebo-controlled trial in humans has been published for any indication; the human record is a few small uncontrolled pilot studies, a retrospective chart review, and a 2015 Phase I study that never reported.
A Phase 2 trial in acute hamstring strain was registered in February 2026. In July 2026 an FDA advisory committee voted 8 to 6 to recommend the compound for the 503A bulks list; the agency has not acted on the recommendation. The compound was listed under WADA's S0 category from 2022.
ENTRIES ABOUT BPC-157 · 4
EVIDENCE
As of October 2026 there is no published randomised controlled trial of BPC-157 in humans. Published human data are small pilot studies; a 2015 Phase I never reported; a Phase 2 hamstring-strain trial was registered in February 2026.
PUBLIC
A 1 October 2026 Q&A from the Harvard T.H. Chan School of Public Health lists BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin among synthetic peptides promoted online for recovery and performance.
REGULATION
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, epitalon and Semax for the 503A bulks list. Emideltide was not recommended.
REGULATION
In September 2023 the FDA placed nineteen peptides in Category 2. In April 2026 it removed twelve of them after their nominations were withdrawn and scheduled advisory meetings to consider adding them to the 503A bulks list.
SOURCES
- Józwiak M. et al. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. 2025. PMC11859134. Peer-reviewed. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11859134/
- ClinicalTrials.gov. NCT07437547. Phase 2, acute grade II hamstring strain. Registered Feb 2026. Registry record. https://clinicaltrials.gov/study/NCT07437547
- NCPA. FDA advisory committee nominates six peptides for pharmacies to compound. 31 Jul 2026. News report. https://ncpa.org/newsroom/qam/2026/07/31/fda-advisory-committee-nominates-six-peptides-pharmacies-compound
REVIEWED 5 Oct 2026 · NEXT REVIEW JAN 2027 · CORRECTIONS ARE LOGGED HERE